Bristol Myers Squibb Company $BMY Shares Acquired by Brookstone Capital Management

Key Points

• Brookstone Capital Management increased its Bristol Myers Squibb stake by 26.9% in the third quarter, adding 25,381 shares to hold 119,608 shares worth approximately $7.46 million. Institutional investors collectively own 76.41% of BMY.
• Analysts remain generally cautious, with a consensus “Hold” rating and an average price target of $64.88; Wells Fargo lowered its target to $60, while Citigroup and HSBC raised theirs.
• BMY shares opened at $61.58, while the company reported strong recent quarterly results and maintained annualized dividends of $2.52 per share, yielding about 4.1%. Investors are also weighing promising oncology developments against cell-therapy safety concerns, expected earnings pressure and high debt.

Brookstone Capital Management increased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 26.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 119,608 shares of the biopharmaceutical company's stock after purchasing an additional 25,381 shares during the quarter. Brookstone Capital Management's holdings in Bristol Myers Squibb were worth $7,464,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ledyard National Bank boosted its holdings in Bristol Myers Squibb by 5.4% in the 3rd quarter. Ledyard National Bank now owns 18,076 shares of the biopharmaceutical company's stock valued at $1,128,000 after purchasing an additional 934 shares in the last quarter. NBT Bank N.A. acquired a new stake in shares of Bristol Myers Squibb in the 3rd quarter valued at approximately $3,303,000. E. Ohman J or Asset Management AB boosted its stake in shares of Bristol Myers Squibb by 5.6% in the third quarter. E. Ohman J or Asset Management AB now owns 73,512 shares of the biopharmaceutical company's stock valued at $4,587,000 after buying an additional 3,900 shares in the last quarter. Reyes Financial Architecture Inc. purchased a new stake in shares of Bristol Myers Squibb in the third quarter valued at approximately $104,000. Finally, Cardinal Capital Management grew its stake in shares of Bristol Myers Squibb by 5.1% during the 3rd quarter. Cardinal Capital Management now owns 110,477 shares of the biopharmaceutical company's stock worth $6,894,000 after purchasing an additional 5,402 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on BMY shares. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, October 12th. Citigroup restated a "neutral" rating and set a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Wells Fargo & Company reduced their price target on shares of Bristol Myers Squibb from $65.00 to $60.00 and set an "equal weight" rating on the stock in a research report on Tuesday, October 13th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 13th. Finally, HSBC reaffirmed a "hold" rating and issued a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a research report on Thursday, September 10th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $64.88.

Insiders Place Their Bets

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company's stock, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers and SystImmune reported that izalontamab brengitecan reduced the risk of disease progression or death by 59% versus chemotherapy in the Phase 3 PANKU-Breast01 trial for advanced HR-positive/HER2-negative breast cancer. The result could strengthen BMY’s oncology pipeline and support a future regulatory filing. Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
• Positive Sentiment: BMY expanded its multi-year collaboration with Tempus AI, licensing multimodal oncology data through 2031 to aid target discovery and drug development. Separately, BMS is collaborating with Pathos AI and Tempus on AI-driven research in Alzheimer’s disease and other neurological conditions, while leading Pathos’s Series E financing and gaining access to its Foundry platform. These deals may improve research productivity and pipeline potential, although financial benefits are longer term. Tempus Expands Strategic Collaboration with Bristol Myers Squibb Pathos AI Announces Strategic Collaborations
• Positive Sentiment: Analyst H. Engel modestly raised Erste Group’s FY2027 EPS forecast to $6.56 from $6.53, matching consensus and suggesting stable expectations for BMY’s earnings power. Bristol Myers Squibb analyst estimate update
• Neutral Sentiment: Phase 1 Breakfree-2 data for the CAR-T therapy zolacabtagene autoleucel in highly active multiple sclerosis provide another pipeline catalyst, but the early-stage study still requires larger and later-stage testing before its commercial value can be assessed. Bristol Myers Squibb Presents Breakfree-2 Results
• Negative Sentiment: Bristol Myers disclosed a patient death in the early-stage cell-therapy study. Even if the event does not ultimately change the program’s development, it introduces a safety overhang and may overshadow the positive efficacy data. Bristol Myers discloses patient death in early-stage cell therapy study
• Negative Sentiment: Pre-earnings coverage anticipates a year-over-year decline in third-quarter earnings, keeping attention on legacy-drug erosion, pipeline execution and BMY’s relatively high debt load. These concerns could outweigh the company’s inexpensive valuation and attractive dividend in the near term. Earnings Preview: Bristol Myers Squibb Q3 Earnings Expected to Decline

Bristol Myers Squibb Trading Down 2.3%

NYSE:BMY opened at $61.58 on Friday. The stock has a market cap of $125.79 billion, a price-to-earnings ratio of 13.56, a price-to-earnings-growth ratio of 0.31 and a beta of 0.19. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The business's 50-day simple moving average is $63.26 and its 200 day simple moving average is $60.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same quarter last year, the firm earned $1.46 EPS. Bristol Myers Squibb's quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.51 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio is 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.